Okomistin eye drops, ear drops, nasal drops 0.01%, 10ml

Ophthalmology

OkomistinЃ, eye drops, ear drops, nasal drops are recommended for the complex treatment of infectious processes in the anterior part of the eye (blepharitis, conjunctivitis, keratitis, keratouveitis), eye injuries, eye burns (thermal and chemical); in the preoperative and postoperative periods for the treatment and prevention of purulent inflammatory lesions of the eyes.

Prevention of neonatal ophthalmia, including gonococcal and chlamydial.

Otorhinolaryngology

The drug is used in the complex treatment of acute sinusitis / rhinosinusitis, exacerbation of chronic sinusitis / rhinosinusitis, acute rhinitis; acute and chronic otitis externa, chronic purulent mesotympanitis, otomycosis.

Ophthalmology

Locally. For adults, for therapeutic purposes, OkomistinЃ is instilled into the conjunctival sac 1-2 drops 4-6 times a day until clinical recovery.

For prophylactic purposes, the drug is instilled 2-3 days before the operation, and also within 10-15 days after the operation, 1-2 drops 3 times a day.

In the treatment of eye burns, after washing the eye with plenty of water, frequent instillations (every 5-10 minutes) are carried out for 1-2 hours. For further treatment, the drug is used 1-2 drops 4-6 times a day.

In pediatric practice, for the treatment of bacterial conjunctivitis in children, OkomistinЃ is instilled into the conjunctival sac 1 drop up to 6 times a day for 7-10 days.

To prevent ophthalmia in newborns, immediately after birth, the child is instilled 1 drop of the drug in each eye 2 times with an interval of 2-3 minutes.

Otorhinolaryngology

Locally. For adults with acute sinusitis / rhinosinusitis, exacerbation of chronic sinusitis / rhinosinusitis, acute rhinitis, infections of the nasal mucosa, OkomistinЃ is instilled 2-3 drops into each nostril, 4-6 times a day. The course of treatment is up to 14 days.

In pediatric practice, for the treatment of acute rhinosinusitis, exacerbation of chronic rhinosinusitis in children over 1 year old, OkomistinЃ is instilled into each nasal passage 1-2 drops up to 4-6 times a day for 10-14 days.

Adults. Locally.

In acute and chronic otitis externa, otomycosis, the drug OkomistinЃ is instilled into the external auditory canal, 5 drops 4 times a day, or, instead of instillation, a gauze turunda moistened with the drug is injected into the external auditory canal 4 times a day. The course of treatment is 10 days.

In adults with chronic mesotympanitis, it is used in complex treatment with the help of hardware ultrasonic irrigation or injection into the tympanic cavity together with antibiotics.

In the absence of positive dynamics (an increase in the severity or the appearance of new signs / symptoms of the disease, the occurrence of complications) on the 3-4th day of therapy using the drug OkomistinЃ, you must consult a doctor!

Active substance:

Benzyldimethyl [3- (myristoylamino) propyl] ammonium chloride monohydrate (in terms of anhydrous substance) - 0.01 g

Excipients:

sodium chloride - 0.90 g, purified water to 100 ml

Individual sensitivity to drug components

Pharmacological properties

Pharmacodynamics.

The main active ingredient of OkomistinЃ is the antiseptic Benzyldimethyl-myristoylamino-propylammonium, which has a pronounced antimicrobial effect against gram-positive and gram-negative, aerobic and anaerobic bacteria in the form of monocultures and microbial associations, including hospital strains with multi-resistance to antibiotics. The drug acts on chlamydia, pathogenic fungi, as well as herpes viruses, adenoviruses. The drug is more effective against gram-positive bacteria, including: staphylococci, streptococci.

It has an antifungal effect on ascomycetes of the genus Aspergillus and genus Penicillium, yeast (Rhodotorula tubra, Torulopsis glabrata) and yeast (Trichophyton rubrum, Trichophyton mentagrophytes, Trichophyton verrucosum, T. schoenleophyte, T. , Microsporum canis), as well as other pathogenic fungi (for example, Pityrosporum orbiculare (Malassezia furfur)) in the form of monocultures and microbial associations, including fungal microflora with resistance to chemotherapeutic drugs.

The action of benzyldimethyl-myristoylamino-propylammonium is based on the direct hydrophobic interaction of the molecule with the lipids of the membranes of microorganisms, leading to their fragmentation and destruction. At the same time, a part of the benzyl dimethyl-myristoylamino-propylammonium molecule, immersed in the hydrophobic section of the membrane, destroys the supra-membrane layer, loosens the membrane, increases its permeability for large-molecular substances, changes the enzymatic activity of the microbial cell, inhibits the enzyme systems, which leads to the inhibition of their microorganism vital functions. Benzyldimethyl-myristoylamino-propylammonium has a high selectivity against microorganisms, because practically does not affect the membranes of human cells, which is associated with a different structure of the latter - a much longer length of lipid radicals,sharply limiting the possibility of hydrophobic interaction of benzyldimethyl-myristoylamino-propylammonium with cells.

The drug reduces the resistance of bacteria and fungi to antibiotics. Benzyldimethyl-myristoylamino-propylammonium has anti-inflammatory and immunoadjuvant effects, enhances local defense reactions, regenerative processes, activates nonspecific defense mechanisms due to modulation of the cellular and local humoral immune response.

Pharmacokinetics.

The drug has a local effect. There are no data on possible penetration into the bloodstream.

Application during pregnancy and during breastfeeding

The use of the drug during pregnancy and during the nursing period is possible only if the intended benefit to the mother outweighs the potential risk to the fetus and child.

Side effect

Allergic reactions are possible. In some cases, you may experience a slight burning sensation, discomfort, which disappear on their own after 15-20 seconds and do not require discontinuation of the drug.

In case of any undesirable phenomena, you should consult a doctor.

Interaction with other medicinal products

When used together, OkomistinЃ increases the effectiveness of topical antibiotics.

Interaction studies of the drug with other drugs have not been conducted.

special instructions

Contact lenses should be removed immediately before the instillation of OkomistinЃ and put on no earlier than 15 minutes after instillation.

To avoid contamination and cross-infection, do not use the same vial to treat eye, nose and / or ear infections at the same time. To prevent contamination of the drug solution during instillation, patients should avoid contact of the dropper tip with the eye and skin. More than one person using the dropper bottle can spread the infection.

Children

The drug can be used in pediatric practice.

Overdose

Not observed.

Influence on the ability to drive vehicles and mechanisms

After using the drug, a temporary decrease in the clarity of visual perception is possible, and until it is restored, it is not recommended to drive a car and engage in activities that require increased attention and reaction.